NSCLC is the leading cause of cancer mortality and represents a major challenge in cancer
therapy. Intrinsic and acquired anticancer drug resistance are promoted by hypoxia and HIF …

Constitutive activation of the epidermal growth factor receptor (EGFR) because of somatic
mutations of the EGFR gene is commonly observed in tumors of non–small cell lung cancer …

Background Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple
different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS …

Cellular metabolic reprogramming is now recognized as a hallmark of tumors. Altered tumor
metabolism determines the malignant biological behaviors and phenotypes of cancer. More …

Metabolic disturbance, particularly of glucose metabolism, is a hallmark of tumors such as
non-small cell lung cancer (NSCLC). Cancer cells tend to reprogram a majority of glucose …

PFKFB3 The PFK2 isoform PFKFB3 is highly expressed in several human cancers, including
colon, prostate, breast, ovary, and thyroid. Most PFK2 isoforms both generate and degrade F …

Simple Summary We propose that PFK1 promotes a positive feedback loop with PI3K/AKT
and YAP/TAZ signaling pathways in cancer cells. Therefore, targeting PFK1 (or its product F …

Oncogenic epidermal growth factor receptor (EGFR) signaling plays an important role in
regulating global metabolic pathways, including aerobic glycolysis, the pentose phosphate …

In non-small-cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and
the tumour suppressor STK11 (also known as LKB1) encoding the kinase LKB1 result in …

Lung cancer is the leading cause of cancer‐related death worldwide, reflecting an
unfortunate combination of very high prevalence and low survival rates, as most cases are …